Harold J. Burstein, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to provide clinical insights on treatment practices for patients with early-stage HER2+ breast cancer.
50 Nipple Sparing Mastectomy With Immediate Lift Using Vertical Technique: Our Initial Experience
Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer
Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.
Dato-DXd Shows Improved Tolerability Vs Chemo in HR+/HER2– Breast Cancer
Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer.
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients